World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
124
Citations
67082
World Ranking
3189
National Ranking
1763

Overview

Robert G. Maki is affiliated with the University of Pennsylvania in the United States. Their research primarily centers on medicine, with a focus on several subfields including pulmonary and respiratory medicine, oncology, pathology and forensic medicine, cardiology and cardiovascular medicine, and rheumatology.

The main topics of Robert G. Maki's work include sarcoma diagnosis and treatment, vascular tumors and angiosarcomas, cardiac tumors and thrombi, cancer genomics and diagnostics, lymphoma diagnosis and treatment, gastrointestinal tumor research and treatment, and cancer immunotherapy and biomarkers.

Robert G. Maki has contributed to multiple recent papers, notably:

  • "A framework for advancing our understanding of cancer-associated fibroblasts," 2020, Nature Reviews. Cancer
  • "The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients," 2020, European Journal of Cancer
  • "Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas," 2020, OncoImmunology
  • "Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology," 2020, Journal of Clinical Oncology
  • "Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma," 2022, Nature Communications

Frequent co-authors collaborating with Robert G. Maki include William D. Tap, Mrinal M. Gounder, Sandra P. D'Angelo, Cristina R. Antonescu, and Silvia Stacchiotti. These partnerships have contributed to a substantial body of work in the field.

Robert G. Maki's publications appear regularly in several venues, with the most frequent venues being the Journal of Clinical Oncology, Clinical Cancer Research, Annals of Oncology, The Oncologist, and Cancer Research.

Best Publications

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • A framework for advancing our understanding of cancer-associated fibroblasts

    Erik Sahai;Igor Astsaturov;Edna Cukierman;David G. DeNardo

  • Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

    Ronald P. DeMatteo;Karla V. Ballman;Cristina R. Antonescu;Robert G. Maki

  • Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    George D Demetri;Peter Reichardt;Yoon-Koo Kang;Jean-Yves Blay

  • Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

    Charles D. Blanke;Cathryn Rankin;George D. Demetri;Christopher W. Ryan

  • NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors

    George D. Demetri;Margaret Von Mehren;Cristina R. Antonescu;Ronald P. DeMatteo

  • Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

    Hussein A Tawbi;Melissa Burgess;Vanessa Bolejack;Brian A Van Tine

  • Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

    Alice T. Shaw;Beow Y. Yeap;Benjamin J. Solomon;Gregory J. Riely

  • NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

    George D. Demetri;Robert S. Benjamin;Charles D. Blanke;Jean Yves Blay

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

    Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi

  • Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas

    Adam Abeshouse;Clement Adebamowo;Sally N. Adebamowo;Rehan Akbani

  • Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation

    Cristina R. Antonescu;Peter Besmer;Tianhua Guo;Knarik Arkun

  • Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

    Michael C. Heinrich;Robert G. Maki;Christopher L. Corless;Cristina R. Antonescu

  • Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

    James E. Butrynski;David R. D’Adamo;Jason L. Hornick;Paola Dal Cin

  • Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas

    Robert G. Maki;J. Kyle Wathen;Shreyaskumar R. Patel;Dennis A. Priebat

  • Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

    George D. Demetri;Margaret von Mehren;Robin L. Jones;Martee L. Hensley

  • Quantitative analysis of cytokine gene expression in rheumatoid arthritis.

    GS Firestein;JM Alvaro-Gracia;R Maki

  • Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial

    Martee L. Hensley;Robert Maki;E. Venkatraman;Gennifer Geller

  • Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.

    Jordi Barretina;Barry S Taylor;Barry S Taylor;Shantanu Banerji;Shantanu Banerji;Alexis H Ramos;Alexis H Ramos

  • Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

    Patrick Schöffski;Sant Chawla;Robert G. Maki;Antoine Italiano

Frequent Co-Authors

Cristina R. Antonescu
Cristina R. Antonescu Memorial Sloan Kettering Cancer Center
George D. Demetri
George D. Demetri Dana-Farber Cancer Institute
Murray F. Brennan
Murray F. Brennan Memorial Sloan Kettering Cancer Center
Samuel Singer
Samuel Singer Memorial Sloan Kettering Cancer Center
Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1
Ronald P. DeMatteo
Ronald P. DeMatteo University of Pennsylvania
Shreyaskumar Patel
Shreyaskumar Patel The University of Texas MD Anderson Cancer Center
Margaret von Mehren
Margaret von Mehren Fox Chase Cancer Center
Antoine Italiano
Antoine Italiano University of Bordeaux
Gary K. Schwartz
Gary K. Schwartz Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA doesn't always mean attending traditional, in-person medical school. Many related health fields offer flexible, affordable online degree pathways that can help you enter the healthcare industry or advance your career.

For example, aspiring pharmacists might explore the cheapest online pharmacy school options for earning a doctoral degree with less student debt. If you are interested in using technology to improve patient care, you can consider a degree in health informatics, where demand continues to rise.

Those curious about the administrative side of healthcare can look into certificate programs and associate degrees in medical coding and billing. The average cost of medical billing and coding program is notably lower than many other healthcare credentials, making it a cost-effective entry point.

For nurses aiming to take their careers further, various online nurse practitioner programs allow you to advance your qualifications and clinical skills without leaving your job. Whether you want to work directly with patients or manage health information, online programs offer flexibility, affordability, and access to growing healthcare careers.

Best Scientists Citing Robert G. Maki

Trending Scientists